Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its continued commitment to people who suffer from migraines during National Migraine & Headache Awareness Month (MHAM). The COVID-19 pandemic has made it
MAPLE GROVE, Minn., June 23, 2020 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced its continued commitment to people who suffer from migraines during National Migraine & Headache Awareness Month (MHAM). The COVID-19 pandemic has made it even more difficult for many patients to access brand name migraine medications. Upsher-Smith's consistent supply of self-administered medications along with the Access Pathways® Program which offers patient savings and support services, helps to ensure that every patient can have access to the migraine medications they deserve. "There is no question that migraine headaches can be hard to live with and treat and managing migraine during the COVID-19 pandemic is no exception," said Rusty Field, President and CEO, Upsher-Smith. "Upsher-Smith remains committed to keeping its portfolio of migraine products available and affordable during these challenging times." The Company's self-administered migraine products include Tosymra® (sumatriptan nasal spray) 10 mg and Zembrace® SymTouch® (sumatriptan) Injection 3 mg for the acute treatment of migraine in adults and Qudexy® XR (topiramate) Extended-Release Capsules for the prevention of migraine headaches in adults and adolescents. Supported by Upsher-Smith's Access Pathways® Program, eligible patients pay $0 Per Prescription* for their migraine medication with the Platinum Pass® Savings Card. Program benefits include:
For additional information on how patients can save on their medication, visit Tosymra, Zembrace SymTouch and Qudexy XR. Important Patient Safety Information for Tosymra® (sumatriptan) Nasal Spray 10 mg What important information should I know about TOSYMRA? TOSYMRA can cause serious side effects, including: heart attack and other heart problems, which may lead to death. Stop using TOSYMRA and get emergency medical help right away if you have any of the following symptoms of a heart attack:
TOSYMRA is not for people with risk factors for heart disease (high blood pressure, high cholesterol levels, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem. Who should not use TOSYMRA?
What should I tell my healthcare provider before taking TOSYMRA? What should I avoid while using TOSYMRA? What are possible side effects of TOSYMRA?
The most common side effects of TOSYMRA include: tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TOSYMRA. For more information, ask your healthcare provider or pharmacist. This is the most important information to know about TOSYMRA but is not comprehensive. For more information, talk to your healthcare provider and read the Patient Information and Instructions for Use for TOSYMRA. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. What is TOSYMRA used for? TOSYMRA is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines. TOSYMRA is not used to treat cluster headaches. TOSYMRA is not used to prevent or decrease the number of migraines you have. It is not known if TOSYMRA is safe and effective in children under 18 years of age. Important Patient Safety Information for Zembrace® SymTouch® IMPORTANT SAFETY INFORMATION What important information should I know about Zembrace® SymTouch®?
Zembrace SymTouch is not for people with risk factors for heart disease (high blood pressure, high cholesterol levels, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem. Who should not use Zembrace SymTouch?
What should I tell my healthcare provider before taking Zembrace SymTouch? What should I avoid while using Zembrace SymTouch? What are possible side effects of Zembrace SymTouch?
The most common side effects of Zembrace SymTouch include pain and redness at your injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired. This is the most important information to know about Zembrace SymTouch but is not comprehensive. For more information, talk to your healthcare provider and read the Patient Information and Instructions for Use for Zembrace SymTouch. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. INDICATION AND USAGE What is Zembrace SymTouch used for? Please see Patient Information, Instructions for Use and full Prescribing Information for Zembrace SymTouch or visit www.Zembrace.com. Important Patient Safety Information for Qudexy® XR (topiramate) Extended-Release Capsules WHAT IS QUDEXY XR? Qudexy® XR (topiramate) Extended-Release Capsules is a prescription medicine used:
WHAT IMPORTANT SAFETY INFORMATION SHOULD I KNOW? Qudexy XR can cause serious side effects, including:
Call your healthcare provider right away if you have any of the above symptoms. Like other antiepileptic drugs, Qudexy XR may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Before taking Qudexy XR, tell your healthcare provider if you have or have had depression, mood problems, or suicidal thoughts or behavior. Call a healthcare provider right away if you have: thoughts about suicide or dying; attempt to commit suicide; have new or worsening depression or anxiety; feel agitated or restless; experience panic attacks, have trouble sleeping (insomnia); have new or worsening irritability; feel or act aggressive, angry, or violent; act on dangerous impulses; experience an extreme increase in activity and talking (mania); or other unusual changes in your behavior or mood. Qudexy XR can harm your unborn baby. All women of childbearing age should talk to their healthcare provider about possible alternative treatments. If you take Qudexy XR during pregnancy, your baby has a higher risk for birth defects called cleft lip and cleft palate. These defects can begin early in pregnancy, even before you know you are pregnant. Also, if you take Qudexy XR during pregnancy, your baby may be smaller than expected at birth; the long-term effects of this are not known. If the decision is made to use Qudexy XR, you should use effective birth control (contraception).Tell your healthcare provider right away if you become, or plan to become pregnant while taking Qudexy XR. The most common side effects of Qudexy XR include: tingling of the arms and legs (paresthesia), not feeling hungry, weight loss, nervousness, nausea, speech problems, tiredness, dizziness, sleepiness/drowsiness, a change in the way foods taste, upper respiratory tract infection, decreased feeling or sensitivity especially in the skin, slow reactions, difficulty with memory, fever, abnormal vision, diarrhea, and pain in the abdomen. These are not all the possible side effects of Qudexy XR. For more information, ask your healthcare provider or pharmacist. Before taking Qudexy XR, tell your healthcare provider about all of your medical conditions, including if you: have had depression, mood problems, or suicidal thoughts or behavior; have kidney problems, kidney stones, or are getting kidney dialysis; have a history of metabolic acidosis (too much acid in the blood); have liver problems; have weak, brittle or soft bones (osteomalacia, osteoporosis, osteopenia, or decreased bone density); have lung or breathing problems; have eye problems, especially glaucoma; have diarrhea; have a growth problem; are on a diet high in fat and low in carbohydrates, which is called a ketogenic diet; are having surgery; are pregnant or planning to become pregnant; or if you are breastfeeding. The medicine in Qudexy XR (topiramate) passes into your breast milk. It is not known if the medicine, topiramate, that passes into breast milk can harm your baby. Talk with your healthcare provider about the best way to feed your baby if you take Qudexy XR. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take metformin (e.g., Glucophage); valproic acid (e.g., Depakene or Depakote); any medicines that impair or decrease your thinking, concentration, or muscle coordination; birth control pills (Qudexy XR may make birth control pills less effective); medicines used to prevent seizures; or any other carbonic anhydrase inhibitors (e.g., zonisamide or acetazolamide). Do not stop Qudexy XR without first talking to a healthcare provider. If you have epilepsy and you stop taking Qudexy XR suddenly, you may have seizures that do not stop. Your healthcare provider will tell you how to stop taking Qudexy XR slowly. Do not drink alcohol while taking Qudexy XR. Qudexy XR and alcohol can cause side effects such as sleepiness and dizziness. Do not drive a car, swim, climb, or operate heavy machinery until you know how Qudexy XR affects you. Qudexy XR can slow your thinking and motor skills, and may affect vision. Even when taking Qudexy XR, some patients with epilepsy will continue to have unpredictable seizures. This is the most important information to know about Qudexy XR but is not comprehensive. For more information, talk to your healthcare provider and read the Medication Guide for Qudexy XR. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. About Upsher-Smith As Upsher-Smith begins its second century in business, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit www.upsher-smith.com. Qudexy, Zembrace, SymTouch, Tosymra, Access Pathways, Platinum Pass and Do More Good are trademarks of Upsher-Smith Laboratories, LLC. *Restrictions apply. Medicare, Medicaid, and other federal and state health care program patients are not eligible. See individual product websites for full program details and quantity limits. PM-000892.01
SOURCE Upsher-Smith Laboratories, LLC |